Targeting Chemoresistance in Advanced Bladder Cancers with a Novel Adjuvant Strategy

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Advanced urinary bladder cancer often exhibits rapid progression and resistance to standard chemotherapy, such as cisplatin and gemcitabine.
• High-grade tumors (> T2a) represent a significant challenge, with frequent treatment failures and limited efficacy of adjuvant therapies.
• Developing novel therapeutic strategies is crucial for improving outcomes in patients with advanced bladder cancer.

Purpose of the Study:

• To evaluate the therapeutic potential of a molecular hybrid of ursolic acid, UA4, against both naïve and gemcitabine-resistant human bladder cancer cell lines.
• To investigate the synergistic effects of UA4 in combination with gemcitabine.
• To elucidate the mechanism of action and assess the in vivo efficacy and toxicity of UA4.

Main Methods:

• In vitro cytotoxicity assays were performed on 5637 and T24 bladder cancer cell lines (WT and GemR variants) treated with UA4.
• Synergistic effects were assessed by combining UA4 and gemcitabine in various sequences.
• In vivo efficacy was evaluated in athymic mice bearing WT and GemR bladder tumors, followed by toxicity assessments.

Main Results:

• UA4 demonstrated potent in vitro cytotoxicity against both gemcitabine-sensitive and resistant bladder cancer cells at 4 µmol/L.
• Pretreatment with UA4 followed by gemcitabine showed synergistic tumor cell killing (>50%) compared to the reverse sequence.
• Oral UA4 administration inhibited tumor growth in vivo, and the combination of UA4 + gemcitabine was more effective against resistant tumors.
• UA4 induced cytotoxic autophagy, moderate apoptosis in T24 cells, mitochondrial dysfunction, and cell cycle arrest, with enhanced effects in combination therapy.
• UA4 was well-tolerated in mice at therapeutic doses, achieving serum levels >1 µmol/L without systemic toxicity.

Conclusions:

• UA4 exhibits significant therapeutic potential as a novel, non-toxic agent for treating high-grade and gemcitabine-resistant bladder cancer.
• The combination of UA4 and gemcitabine offers a promising synergistic approach for overcoming therapeutic resistance.
• Further investigation into UA4's mechanisms, including its impact on mitochondrial function and autophagy, is warranted for clinical translation.